Toxoplasmosis is increasingly diagnosed after hematopoietic stem cell transplantation (HSCT) and is associated with considerable morbidity and mortality. In the majority of cases, reactivation of latent disease secondary to impaired cellular and humoral immunity after HSCT is believed to be the main pathogenetic mechanism. Hence, primary toxoplasmosis is rarely considered in the differential diagnosis of infections after HSCT in a recipient who is seronegative for Toxoplasma gondii pre-transplant. We herein report a seronegative patient with acute T-cell lymphoblastic leukemia, who developed primary disseminated toxoplasmosis 5 months after HSCT from a seronegative unrelated donor. A review of all reported cases of primary toxoplasmosis after HSCT revealed significantly increased morbidity and mortality. Patients with negative pre-transplant Toxoplasma serology should therefore be considered at risk for toxoplasmosis after allogeneic HSCT. Possible prevention and monitoring strategies for seronegative recipients are reviewed and discussed in detail.

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.12043DOI Listing

Publication Analysis

Top Keywords

disseminated toxoplasmosis
8
toxoplasmosis allogeneic
8
stem cell
8
cell transplantation
8
morbidity mortality
8
primary toxoplasmosis
8
hsct
6
seronegative
5
toxoplasmosis
5
allogeneic stem
4

Similar Publications

A 54-year-old woman underwent cord blood transplantation in second remission of acute myeloid leukemia. She tested positive for anti-toxoplasma IgG antibody before transplantation. After neutrophil engraftment, she complained of foggy vision, but brain MRI showed no abnormality.

View Article and Find Full Text PDF

Fatal disseminated infection in a cat from Madrid, Spain.

JFMS Open Rep

January 2025

NEIKER-BRTA (Instituto Vasco de Investigación y Desarrollo Agrario - Basque Research and Technology Alliance), Derio, Bizkaia, Spain.

Case Summary: is a globally distributed apicomplexan protozoan infecting all warm-blooded animals. Cats are the definitive host, susceptible to clinical disease. In Spain, studies have shown the widespread presence of IgG antibodies in cats but there are no published data on clinical toxoplasmosis in cats from Spain.

View Article and Find Full Text PDF
Article Synopsis
  • Drug development for congenital toxoplasmosis is challenging due to high adverse effects and poor efficacy of first-line therapies; bumped kinase inhibitors (BKIs) like BKI-1748 may offer a new treatment option.
  • In a study involving 19 pregnant sheep, those treated with BKI-1748 after infection showed lower fever and immunological responses compared to untreated counterparts.
  • The treated group had a higher percentage of healthy lambs at delivery and showed no evidence of congenital transmission of the parasite, unlike the untreated group where parasite DNA was detectable.
View Article and Find Full Text PDF
Article Synopsis
  • A 55-year-old woman with HIV/AIDS, adhering to her antiretroviral therapy, was hospitalized due to swallowing difficulties and swollen lymph nodes, revealing a rare case of disseminated histoplasmosis and suspected cerebral toxoplasmosis.
  • The diagnosis was confirmed through various tests, including a biopsy, (1-3) -β-glucan assay, and imaging studies.
  • This case underscores the challenges of managing opportunistic infections during immune recovery in HIV patients and the importance of vigilant monitoring and comprehensive diagnostics.
View Article and Find Full Text PDF

Alternative Pneumocystis Pneumonia Prophylaxis in Solid Organ Transplants.

Transpl Infect Dis

November 2024

Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background: Despite limited data supporting use in solid organ transplant (SOT) recipients, atovaquone and dapsone are often used as alternatives to trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis.

Methods: This single-center, retrospective cohort study describes a multi-organ program's experience with alternative PJP prophylaxis. Adult SOT recipients transplanted November 13, 2020 to November 13, 2022 who received non-TMP-SMX PJP prophylaxis and had > 1 year follow-up were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!